Abstract
Molecular imaging of biological processes may allow detection of therapy effects before the tumor is reduced in size. The most frequently used PET tracer in oncology, 2-[18F]fluoro-2-deoxyglucose (FDG), suffers from low specificity due to uptake in inflammatory cells. The proliferation marker, 3-[18F]fluoro-3-deoxy-L-thymidine (FLT), is less influenced by the inflammatory response following therapy but here disease- and drug-specific effects need to be considered. Since cancer therapy mainly intends to eliminate cancer cells, imaging of cell death offers a direct way to image therapy response. This review gives an overview of the radiopharmaceutical development and in vivo evaluation of radioligands that have emerged so far for detection and assessment of apoptosis and necrosis. Two radiopharmaceuticals that can image cell death have made it to clinical trials for follow up of tumor treatment: i) 99mTc-and 123I-labelled AnxA5 for the response to treatment of for example lymphoma and lung cancer and ii) 18F-ML10 for the evaluation of brain tumors post-radiation. Other agents need further optimization.
Keywords: Apoptosis, AnnexinA5, 18F-ML10, molecular imaging of therapy response, F]fluoro-3'-deoxy-L-thymidine (FLT), cancer cells, Molecular imaging of biological processes, cell death offers, radiopharmaceutical development, tumor treatment, lymphoma, clinical trials, morphologic imaging techniques, lung cancer, computed tomography (CT)
Current Pharmaceutical Biotechnology
Title: Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?
Volume: 13 Issue: 4
Author(s): Marijke De Saint-Hubert, Matthias Bauwens, Alfons Verbruggen and Felix M. Mottaghy
Affiliation:
Keywords: Apoptosis, AnnexinA5, 18F-ML10, molecular imaging of therapy response, F]fluoro-3'-deoxy-L-thymidine (FLT), cancer cells, Molecular imaging of biological processes, cell death offers, radiopharmaceutical development, tumor treatment, lymphoma, clinical trials, morphologic imaging techniques, lung cancer, computed tomography (CT)
Abstract: Molecular imaging of biological processes may allow detection of therapy effects before the tumor is reduced in size. The most frequently used PET tracer in oncology, 2-[18F]fluoro-2-deoxyglucose (FDG), suffers from low specificity due to uptake in inflammatory cells. The proliferation marker, 3-[18F]fluoro-3-deoxy-L-thymidine (FLT), is less influenced by the inflammatory response following therapy but here disease- and drug-specific effects need to be considered. Since cancer therapy mainly intends to eliminate cancer cells, imaging of cell death offers a direct way to image therapy response. This review gives an overview of the radiopharmaceutical development and in vivo evaluation of radioligands that have emerged so far for detection and assessment of apoptosis and necrosis. Two radiopharmaceuticals that can image cell death have made it to clinical trials for follow up of tumor treatment: i) 99mTc-and 123I-labelled AnxA5 for the response to treatment of for example lymphoma and lung cancer and ii) 18F-ML10 for the evaluation of brain tumors post-radiation. Other agents need further optimization.
Export Options
About this article
Cite this article as:
De Saint-Hubert Marijke, Bauwens Matthias, Verbruggen Alfons and M. Mottaghy Felix, Apoptosis Imaging to Monitor Cancer Therapy: The Road to Fast Treatment Evaluation?, Current Pharmaceutical Biotechnology 2012; 13 (4) . https://dx.doi.org/10.2174/138920112799436320
DOI https://dx.doi.org/10.2174/138920112799436320 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Treatment Concepts of CML
Current Cancer Drug Targets RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions
Combinatorial Chemistry & High Throughput Screening Cell-in-cell phenomenon: A New Paradigm in Life Sciences.
Current Molecular Medicine Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Dose and Sequence Dependent Synergism from the Combination of Oxaliplatin with Emetine and Patulin Against Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: Imaging Agents for Apoptosis (Guest Editor: Wenbin Zeng)]
Anti-Cancer Agents in Medicinal Chemistry Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Effects of Conjugated Linolenic Acids (CLN) Occurring in Plant Seed Oils
Current Nutrition & Food Science CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy A Review of the Primer Approximation Multiplex PCR (PAMP) Technique for Detecting Large Scale Cancer Genomic Lesions
Current Bioinformatics Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Innovations in siRNA Research: A Technology Comes of Age
Recent Patents on Anti-Infective Drug Discovery From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology